Characteristics of low-grade NHL patients: follow-up at 1 year
| Patient no.* . | Stage atdiagnosis† . | One-y follow-up‡(stage in 2005) . | Vδ1§ . | ULBP2/3mRNA‖ . | Surface¶ULBP2/3 . | Serum IL-4level,# pg/mL . | Chromosomeabnormalities** . |
|---|---|---|---|---|---|---|---|
| Group 1 | |||||||
| 2 | FL IVA | SD | 90.6 | +/+ | +/+ | 23.7 | — |
| 4 | FL IB | SD | 100.3 | −/+ | −/+ | 30.7 | — |
| 5 | FL IVA | SD | 101.6 | +/− | +/− | 18.1 | — |
| 7 | FL IVB | SD | 97.8 | −/+ | −/+ | 15.3 | — |
| 8 | FL II | SD | 220.5 | +/+ | +/+ | 8.9 | — |
| 9 | FL IIIs | SD | 100.1 | +/+ | +/+ | 13.7 | — |
| 11 | FL III | SD | 124.6 | +/+ | +/+ | 54.5 | — |
| 13 | FL III | SD | 58.4 | −/+ | −/+ | 7.9 | — |
| 14 | FL IVA | SD | 110.4 | +/+ | +/+ | 12.0 | — |
| 15 | FL I | SD | 132.6 | +/− | +/− | 15.6 | — |
| 17 | MT II | SD | 106.8 | +/+ | +/− | 18.6 | — |
| 18 | MT II | SD | 99.6 | +/+ | −/+ | 14.6 | — |
| 20 | MZ II | SD | 112.1 | +/− | +/− | 9.8 | — |
| 23 | MZ I | SD | 141.4 | +/+ | +/+ | 9.6 | — |
| Group 2 | |||||||
| 1 | FL IIIB | PD (IV) | 9.9 | −/+ | −/− | 2.2 | t(14;18) |
| 3 | FL II | PD (III) | 12.1 | −/+ | −/− | 6.7 | t(14;18) |
| 6 | FL IIB | PD (III) | 10.8 | +/− | −/− | 2.2 | t(14;18); t(8;14) |
| 10 | FL IVA | SD | 18.9 | +/− | +/− | 2.5 | t(14;18) |
| 19 | MT II | PD (III) | 0.1 | −/+ | −/− | 0.0 | t(14;18) |
| 22 | MZ IVA | PD (IVB) | 0.1 | +/− | +/− | 3.9 | t(14;18) |
| Patient no.* . | Stage atdiagnosis† . | One-y follow-up‡(stage in 2005) . | Vδ1§ . | ULBP2/3mRNA‖ . | Surface¶ULBP2/3 . | Serum IL-4level,# pg/mL . | Chromosomeabnormalities** . |
|---|---|---|---|---|---|---|---|
| Group 1 | |||||||
| 2 | FL IVA | SD | 90.6 | +/+ | +/+ | 23.7 | — |
| 4 | FL IB | SD | 100.3 | −/+ | −/+ | 30.7 | — |
| 5 | FL IVA | SD | 101.6 | +/− | +/− | 18.1 | — |
| 7 | FL IVB | SD | 97.8 | −/+ | −/+ | 15.3 | — |
| 8 | FL II | SD | 220.5 | +/+ | +/+ | 8.9 | — |
| 9 | FL IIIs | SD | 100.1 | +/+ | +/+ | 13.7 | — |
| 11 | FL III | SD | 124.6 | +/+ | +/+ | 54.5 | — |
| 13 | FL III | SD | 58.4 | −/+ | −/+ | 7.9 | — |
| 14 | FL IVA | SD | 110.4 | +/+ | +/+ | 12.0 | — |
| 15 | FL I | SD | 132.6 | +/− | +/− | 15.6 | — |
| 17 | MT II | SD | 106.8 | +/+ | +/− | 18.6 | — |
| 18 | MT II | SD | 99.6 | +/+ | −/+ | 14.6 | — |
| 20 | MZ II | SD | 112.1 | +/− | +/− | 9.8 | — |
| 23 | MZ I | SD | 141.4 | +/+ | +/+ | 9.6 | — |
| Group 2 | |||||||
| 1 | FL IIIB | PD (IV) | 9.9 | −/+ | −/− | 2.2 | t(14;18) |
| 3 | FL II | PD (III) | 12.1 | −/+ | −/− | 6.7 | t(14;18) |
| 6 | FL IIB | PD (III) | 10.8 | +/− | −/− | 2.2 | t(14;18); t(8;14) |
| 10 | FL IVA | SD | 18.9 | +/− | +/− | 2.5 | t(14;18) |
| 19 | MT II | PD (III) | 0.1 | −/+ | −/− | 0.0 | t(14;18) |
| 22 | MZ IVA | PD (IVB) | 0.1 | +/− | +/− | 3.9 | t(14;18) |
SD indicates stable disease; PD, progressive disease; and —, no abnormalities.
The number is referred to patients listed in Table 1.
Diagnosis and stage are defined according to the REAL classification.25
Stage after 1 year.
Absolute number of peripheral-blood Vδ1 T lymphocytes/μL at the beginning of the study (early 2004); these numbers did not significantly change after 1 year (2005). Mean ± SD: group 1, 114.0 ± 35.1; group 2, 8.6 ± 6.7; group 1 versus group 2, P < .01. Number of Vδ1 T cells in healthy donors, 15 ± 1.
ULBP2 or ULBP3 mRNA expression evaluated by PCR; +, positive; −, negative.
ULBP2 or ULBP3 surface expression evaluated by immunofluorescence and cytofluorimetric analysis with the specific anti-ULBP2 mAb labeled with Alexa Fluor 594; results are expressed as positive (+), that is. MFI >25 (au); negative (−), that is MFI <20; MFI of Alexa Fluor-labeled isotype-matched irrelevant mAb was 15 au.
IL-4 was measured by enzyme-linked immunosorbent assay in the sera of NHL patients in 2004; results are expressed as picograms per milliliter. Mean ± SD: group 1, 18.0 ± 11.7; group 2, 2.9 ± 2.0; group 1 versus group 2; P < .01. IL-4 in the serum of healthy donors was undetectable.
Translocations: t(14;18), Bcl-2; t(3;14) Bcl-6; t(8;14) c-myc.28